During a fireside chat, Conexeu Sciences Inc. (Nasdaq: CNXU) CEO Miles Harrison discussed the company's preclinical-stage tissue regeneration technology, which aims to address large-volume tissue restoration. Harrison noted a growing demand for treatments to restore lost facial and body volume, driven by the widespread use of GLP-1 weight-loss drugs. The company anticipates an FDA 510(k) submission in early 2027 for its initial indication, with further plans to expand into dental and veterinary markets.